Evidence map›Paper›PMID 27000559›Full record

ReviewAngewandte Chemie (International ed. in English)2016

Targeting Antibiotic Resistance.

Mathieu F Chellat, Luka Raguž, Rainer Riedl

Abstract readReview
In one paragraph

Review in Angewandte Chemie (International ed. in English), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. A New Ursane-Type Pentacyclic Triterpenoid from the Tree Bark ofInternational journal of molecular sciences · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Antibacterial activity and biosynthetic potential of Streptomyces sp. PBR19, isolated from forest rhizosphere soil of Assam.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mathieu F ChellatInstitute of Chemistry and Biotechnology, Center for Organic and Medicinal Chemistry, Zurich University of Applied Sciences (ZHAW), Einsiedlerstrasse 31, 8820, Wädenswil, Switzerland.ORCID 0000-0002-3802-672X
Luka RagužInstitute of Chemistry and Biotechnology, Center for Organic and Medicinal Chemistry, Zurich University of Applied Sciences (ZHAW), Einsiedlerstrasse 31, 8820, Wädenswil, Switzerland.ORCID 0000-0001-5383-3012
Rainer RiedlInstitute of Chemistry and Biotechnology, Center for Organic and Medicinal Chemistry, Zurich University of Applied Sciences (ZHAW), Einsiedlerstrasse 31, 8820, Wädenswil, Switzerland. rainer.riedl@zhaw.ch.ORCID 0000-0003-2534-1963

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health. The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics. More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power. In addition, industry pipelines for the development of novel antibiotics have run dry over the past decades. A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial ProteinsDrug DesignDrug Resistance, Multiple, BacterialMacrolidesMolecular Dynamics SimulationOrganophosphatesOxazolesOxazolidinonesStructure-Activity RelationshipAnti-Bacterial AgentsBacterial ProteinsMacrolidesOrganophosphatesOxazolesOxazolidinonestedizolid phosphateantibiotic resistanceantibioticsdrug designmedicinal chemistrystructure-activity relationships

Identifiers

PMID27000559
PMCPMC5071768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.